Prognostic Value of Systemic Inflammation Score for Esophageal Cancer Patients Undergoing Surgery: A Systematic Review and Meta-Analysis

Figures & data

Table 1. Details of included studies.

Study	Location	Study population	Tumor stage	SIS definition	Timing of SIS	Sample size	Age (Years)	Male gender (%)	Adeno-carcinoma (%)	Poorly differentiated (%)	Vascular invasion (%)	Lymphatic invasion (%)	AC (%)	Median follow-up (months)	NOS score
Aoyama 2022[11]	Japan	Esophageal cancer patients undergoing surgery	I-IV	NA	Pre-surgery	168	NA	NA	NA	NA	NA	NA	100	NA	–
Xiong 2021[12]	China	Adenocarcinoma of EGC undergoing surgery	I-III	0: Al ≥ 4 g/dl & LMR ≥ 3.4 1: either Al ≥ 4 g/dl or LMR ≥ 3.4 2: Al <4 g/dl & LMR < 3.4	Pre-surgery	317	63.4	83.6	100	31.8	37.9	53.7	52.1	Up to 6 years	8
Tsuchiya 2021[16]	Japan	Esophageal cancer patients undergoing surgery	I-IV	0: Al ≥ 4 g/dl & LMR ≥ 4.44 1: either Al ≥ 4 g/dl or LMR ≥ 4.44 2: Al <4 g/dl & LMR < 4.44	Pre-surgery	189	NR	84.1	3.7	NR	NR	NR	30.7	46.5 months	8
Nomoto 2021[13]	Japan	Esophageal cancer patients undergoing surgery	I-IV	0: Al ≥ 4 g/dl & LMR ≥ 3.3 1: either Al ≥ 4 g/dl or LMR ≥ 3.3 2: Al <4 g/dl & LMR < 3.3	Pre-surgery	509	66.3	88	NR	NR	NR	NR	NR	4 years	8
Kanda 2019[17]	Japan	Esophageal squamous cell cancer patients undergoing surgery	I-IV	0: Al ≥ 4 g/dl & LMR ≥ 3.4 1: either Al ≥ 4 g/dl or LMR ≥ 3.4 2: Al <4 g/dl & LMR < 3.4	Pre-surgery	443	66.1	84.4	0	11.3	23	53.5	NR	41.8 months	8
Fu 2019[18]	China	Esophageal squamous cell cancer patients undergoing surgery	I-IV	0: Al ≥ 3.7 g/dl & LMR ≥ 3.94 1: either Al ≥ 37 g/dl or LMR ≥ 3.94 2: Al <3.7 g/dl & LMR < 3.94	Pre-surgery	357	57	78.2	0	12.6	87.4	NR	60	58 months	8
Guo 2018[19]	China	Esophageal squamous cell cancer patients undergoing surgery	I-IV	NR	Pre-surgery	277	62	78	0	28	NR	NR	NR	36	7
Han 2015[20]	China	Esophageal squamous cell cancer patients undergoing surgery	I-IV	NR	Pre-surgery	206	60.5	80.1	0	29.6	NR	NR	36.9	39.5	7

AC, adjuvant chemotherapy; Al, albumin; LMR, lymphocyte-monocyte ratio; SIS, systemic inflammation score; NOS, Newcastle Ottawa scale; NR, not reported; NA, not available.

Figure 1. Study flowchart.

Figure 2. Meta-analysis of OS for SIS score 1-2 vs O in esophageal cancer patients.

Figure 3. Meta-analysis of OS for SIS score 2 vs 1-2 in esophageal cancer patients.

Figure 4. Meta-analysis of DFS for SIS score 1-2 vs O in esophageal cancer patients.

Aoyama T, Ju M, Komori K, et al. The systemic inflammation score is an independent prognostic factor for esophageal cancer patients who receive curative treatment. Anticancer Res. 2022;42(5):2711–2717. doi:10.21873/ANTICANRES.15749.

 PubMed Web of Science ®Google Scholar

Xiong J, Kang W, Ma F, et al. Modified systemic inflammation score is an independent predictor of long-term outcome in patients undergoing surgery for adenocarcinoma of the esophagogastric junction. Front Surg. 2021;8:622821. doi:10.3389/fsurg.2021.622821.

 PubMed Web of Science ®Google Scholar

Tsuchiya N, Kunisaki C, Sato S, et al. Feasibility of esophagectomy for esophageal cancer in elderly patients: a case-control study. Langenbecks Arch Surg. 2021;406(8):2687–2697. doi:10.1007/S00423-021-02271-0.

 PubMed Web of Science ®Google Scholar

Nomoto D, Baba Y, Akiyama T, et al. Adapted systemic inflammation score as a novel prognostic marker for esophageal squamous cell carcinoma patients. Ann Gastroenterol Surg. 2021;5(5):669–676. doi:10.1002/AGS3.12464.

 PubMed Web of Science ®Google Scholar

Kanda M, Koike M, Tanaka C, et al. Modified Systemic Inflammation Score is Useful for Risk Stratification After Radical Resection of Squamous Cell Carcinoma of the Esophagus. Ann Surg Oncol. 2019;26(13):4773–4781. doi:10.1245/S10434-019-07914-7.

 PubMed Web of Science ®Google Scholar

Fu X, Li T, Dai Y, Li J. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma. BMC Cancer. 2019;19(1):721. doi:10.1186/s12885-019-5940-6.

 Google Scholar

Guo XW, Liu YC, Gao F, et al. Pretreatment NRS-2002 scores combined with hematologic inflammation markers are independent prognostic factors in patients with resectable thoracic esophageal squamous cell carcinoma. Cancer Manag Res. 2018;10:2409–2418. doi:10.2147/CMAR.S167179.

 PubMed Web of Science ®Google Scholar

Han L, Song Q, Jia Y, et al. The clinical significance of systemic inflammation score in esophageal squamous cell carcinoma. Tumour Biol. 2016;37(3):3081–3090. doi:10.1007/S13277-015-4152-1.

 PubMedGoogle Scholar

Availability of data and materials

The data that support the findings of this study are openly available in [PROSPERO] at [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022340717], reference number [No CRD42022340717].e